X-Message-Number: 12069
Date: Mon, 5 Jul 1999 12:49:58 EDT
Subject: 21CM, ABS, BT etc

There has been an announcement by Kent et al concerning Advanced BioSciences 
(ABS) etc.(See the Sci.Cryonics newsgroup 04 July 1999 post from 
). I thought it would appear on Cryonet today (July 5), but it 
hasn't, so I append it below. In view of this, it may be helpful for me to 
review the present and future state of affairs, especially from the 
standpoint of Cryonics Institute and of prospective members of all cryonics 

In the past, Alcor and CryoCare have claimed "state of the art" or "best" 
cryostasis procedures. The main current refrain is that recent advances at 
21st Century Medicine (21CM), including new cryoprotectants and ice blockers, 
will soon be the basis for the best procedures. Details are still shrouded in 
secrecy pending patent protection and commercial exploitation, but will 
eventually emerge. The first (and possibly the only) cryonics organizations 
to offer the new procedures, based on the announcement, will be Alcor and 
CryoCare, through BioTransport (BT), although there have been repeated 
statements by BT leaders that they hope to make arrangements with other 
cryonics organizations also.

Now let me review the general stance of Cryonics Institute (CI). Our current 
procedures are based on our own research, repeated and evaluated by Yuri 
Pichugin et al, professional cryobiologists in the Ukraine. (Pichugin is 
currently working for a U. Cal.  group contractually associated with 21CM. 
21CM's chief cryobiologist, Greg Fahy, is one of the co-principal 
investigators supervising Pichugin's work.) The perfusate used is based on 
glycerol, and the details of procedure were adopted after trying many 
variations. Other organizations have reported different procedures, alleged 
to be better, but we rely on our own observations. Some of the alleged 
improvements produced worse results when we tried them.

The "state space" of cryonics experimentation is enormous. As far as I know, 
no one can possibly, in a reasonable time and with realistic resources, check 
them all out adequately. We can only test the most promising variations, with 
new ideas as they occur to us. Our results have been relatively good (read 
the "Research" pages on our web site), but of course nowhere near perfect. We 
are currently engaged in new research on a range of parameters, including 
acceptable methods of ramping up glycerol concentration and including the use 
of different cryoprotectants. Although our resources are orders of magnitude 
smaller than those of 21CM, I think we have an excellent chance at least of 
making improvements, and possibly of making breakthroughs. 

Our research agenda for the future also includes procedures that may prove 
LESS costly than current systems, even if results are worse by some criteria. 
For example, it may turn out that some combination of chemical fixation, 
drying, and cold storage (at relatively high temperature) will result in good 
retention of structure, even though inferior retention of function. For those 
who cannot afford anything else, this could be a life saver. It could also be 
important in terms of politics and public relations, since it would tend to 
soften the perception of cryostasis as a perquisite only for the rich. 

So we intend to continue to offer our current procedures, and improvements 
thereon, at our current prices, which are much lower than those of other 
organizations. We may even offer lower-cost procedures, as noted just above. 
We also intend to make available to our members, as feasible, all the other 
options, including the more expensive ones likely to emerge from 21CM 

Exactly how this will develop depends on many factors not yet known. For 
example, what will be the pricing structure emerging from the 21CM-ABS-BT 
axis? Will 21CM  sell or license to anyone other than ABS? Will contractual 
arrangements allow ABS to sell or license to other organizations in 
competition with BT? For example, one of the options CI might want is to 
license 21CM patents for our own direct use, not through BT. Etc., etc.

Possible pricing and policy could cover an enormous range. From the 
standpoint of 21CM as a business, they want to recoup their research 
investment as quickly as possible, and maybe they could sell their system to 
one billionaire for $10 million. On the other hand, they also want to 
maximize future revenues, so maybe they will settle for a near-term loss in 
order to build business. Maybe their potential patent protection is nearly 
iron-clad--or maybe it isn't. Protecting patent rights is notoriously 
difficult and expensive. Maybe other people can patent variations and then 
negotiate for a modus vivendi. Maybe entirely different and equally good or 
better methods will be discovered by others--and there are indeed others 
already active. Or if one company really develops an effective monopoly on 
the best procedures, then anti-trust questions could arise. It's pretty murky 
out there, and we'll just have to see what develops, and adjust.

The bottom line, again, is that CI is determined, within its resources and 
the constraints of reality, to make available to CI members every option that 
appears to hold promise.

Robert Ettinger
Cryonics Institute
Immortalist Society

BioTransport Letter of Agreement
Date: Sun, 04 July 1999 08:15 PM EDT
Message-id: <7lotfc$onl$>

As of July 1st, 1999, principals of BioTransport, Inc.,
CryoCare Foundation, and Advanced BioSciences, Inc. have
signed a binding letter of intent affirming that Advanced
BioSciences intends to sublicense new cryopreservation
technology to BioTransport, and BioTransport intends to use
this technology to provide enhanced service to Alcor and
CryoCare members.
While a formal contract has not been negotiated, principals
at the three companies are optimistic that such a contract
can exist by the end of this year.
BioTransport was formed initially by Fred Chamberlain, Linda
Chamberlain, Joe Hovey, and Michael Riskin, of Alcor, as an
independent provider of human cryopreservation services
including remote standby, transport, perfusion, and cooldown.
Michael Riskin, who is now CFO and Vice President of
BioTransport, has taken a highly active role this year in
developing the new company as an independent provider of
human cryopreservation services including remote standby,
transport, perfusion, and cooldown. It will first offer its
services to CryoCare and Alcor members, with others to follow
if satisfactory contracts can be negotiated.
Advanced BioSciences was created this year to develop
cryonics applications from recent research at 21st Century
Medicine. 21st now conducts only cryobiology research, having
spun off its hypothermia and resuscitation projects into a
new, separate company named Critical Care Research. 21st has
no involvement in cryonics and will be launching sales of its
first product this summer, the SuperCool X-1000 Ice Blocker.
CryoCare Foundation and the Alcor Foundation are cryonics
organizations whose needs are complementary. Alcor has
expressed interest in results of recent research, while
CryoCare wishes to restore its ability to deliver remote-
standby service and enhance its cryopreservation services.
BioTransport should be able to satisfy these needs on a basis
that will be mutually beneficial.
In the future, BioTransport and/or Advanced BioSciences may
negotiate agreements with additional clients. Currently,
however, Alcor and CryoCare are the only cryonics
organizations negotiating to receive improved technology from
Advanced BioSciences and cryopreservation service from
This announcement is made jointly by Saul Kent, Chairman and
CEO of Advanced BioSciences and 21st Century Medicine;
Charles Platt, President of CryoCare; and Michael Riskin, CFO
and Vice President for Business Development at BioTransport.

Rate This Message: http://www.cryonet.org/cgi-bin/rate.cgi?msg=12069